Retrospective Cohort Analysis of ATTR-CM

Consecutive patients followed at the Cardiac Amyloidosis Clinic at our institution with a diagnosis of ATTR-CM from November 2016 to January 2021 were included in this retrospective cohort analysis. Patients with both ATTR subtypes were included if they met the following criteria; (1) exclusion of light-chain (AL) amyloidosis through the absence of serum and urine monoclonal protein, (2) evidence of cardiac amyloidosis by either myocardial biopsy or positive technetium-99 m-pyrophosphate nuclear scintigraphy defined by grade 2–3 myocardial uptake or heart-to-contralateral lung ratio > 1.5, as previously described [10 (link)], and (3) either hATTR or wtATTR based upon results of genetic testing or proteomic analysis by mass spectrometry performed on biopsy tissue samples. Patients with non-ATTR subtypes of amyloidosis or those with < 12 months clinical follow-up were excluded. Clinical, medication, biochemical and cardiac imaging data were collected at the time of ATTR-CM diagnosis. This study was approved by the University of Calgary Research Ethics Board, and the requirement for informed written patient consent was waived.

Free full text: Click here

Hassan R., Miller R.J., Howlett J.G., White J.A, & Fine N.M. (2023). Prevalence, incidence and clinical outcomes of epicardial coronary artery disease among transthyretin amyloidosis cardiomyopathy patients. BMC Cardiovascular Disorders, 23, 124.

Publication 2023

Al amyloidosis Amyloidosis Attr Biopsy Diagnosis Heart Light Lung Mass spectrometry Medication Myocardial Patient Protein Scintigraphy Serum Technetium 99 m pyrophosphate Tissue Urine

Corresponding Organization :

Other organizations : Alberta Health Services, South Health Campus, University of Calgary

Top 5 similar protocols

Variable analysis

independent variables

Exclusion of light-chain (AL) amyloidosis through the absence of serum and urine monoclonal protein
Evidence of cardiac amyloidosis by either myocardial biopsy or positive technetium-99 m-pyrophosphate nuclear scintigraphy defined by grade 2–3 myocardial uptake or heart-to-contralateral lung ratio > 1.5
Either hATTR or wtATTR based upon results of genetic testing or proteomic analysis by mass spectrometry performed on biopsy tissue samples

dependent variables

Clinical, medication, biochemical and cardiac imaging data were collected at the time of ATTR-CM diagnosis

control variables

Consecutive patients followed at the Cardiac Amyloidosis Clinic at the institution with a diagnosis of ATTR-CM from November 2016 to January 2021 were included
Patients with non-ATTR subtypes of amyloidosis or those with < 12 months clinical follow-up were excluded

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!